PA-SYNERGIS-SOFTWARE
28.10.2020 13:23:34 CET | Business Wire | Press release
Synergis Software , a global leader in engineering information management and product data management (PDM), today announced that its flagship product, Adept, has earned 21 top placements in G2 Crowd ’s Fall 2020 Grid Reports.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005422/en/
The reports, which are based on real customer reviews, highlight Adept’s leadership in ease of use, ease of setup, fastest implementation, best support and best relationship as some of the key differentiators compared to other products on the market.
Adept earned Leader status in Product Data Management (PDM) and Enterprise Content Management (ECM), and High Performer status in Construction Drawing Management.
“We're committed to helping clients become more efficient, secure and collaborative, and reports like this help us understand what we're doing well and how we can improve,” said Scott Lamond, vice president of marketing at Synergis Software. “We’re energized and honored that the voice of the customer has us ranked at the top of our field.”
Adept also achieved an exceptional 77 on the G2 Net Promoter Scorecard (NPS).
According to G2, “The purpose of NPS is to gauge customer loyalty to a brand, and how likely they are to recommend your product to a peer. An NPS at-or-above 70 is considered “world class.” Essentially, this means nearly every customer would advocate for that product."
Here’s what some Adept customers had to say:
- “Data is the cornerstone of any business today and not securing it is a huge risk. If you want to do it right and do it well, the Adept platform is the gold-standard.”
- “No other software company anywhere works as closely with their customers. For a system that your business cannot operate without, this is invaluable.”
- “An immediate 30% gain in user efficiency”
Adept earned top honors in the following rankings:
Product Data Management - Best Usability, Easiest Setup, Fastest Implementation, Most Implementable, Ease of Administration, Ease of Doing Business, Quality of Support, Best Relationship, Most Likely to Recommend, Highest Net Promoter Score
Construction Drawing Management - Easiest to Use, Best Meets Requirements, Easiest Setup, Best Support, Highest User Adoption, Easiest to do Business With, Product Going in the Right Direction, Most likely to Recommend, Highest Net Promoter Score
Enterprise Content Management - Ease of Doing Business With, Best Search Capabilities
To see how Adept stacks up, download the full comparison report .
You can read more customer feedback on G2’s Adept review page .
Learn more about G2’s scoring methodology here .
About Synergis Software
Synergis Software is the leader in engineering document management and product data management, helping businesses become more efficient, secure and collaborative. The flagship product, Adept, gets everyone on the same page, simplifying the way organizations find, manage, share and integrate enterprise content. Adept streamlines engineering change management, protects intellectual property, and provides data insights to improve decision making. Adept is integrated with AutoCAD®, Autodesk Inventor®, SolidWorks® and MicroStation®, and has been battle tested by engineers for over 30 years in customers like Dow Chemical, Con Edison, General Mills, Bayer, and Nucor Steel.
G2 Crowd
G2 Crowd , the world's leading business solution review platform, leverages more than 790,000 user reviews to drive better purchasing decisions. G2 aims to bring authenticity and transparency to the business marketplace by leveraging peer reviews, satisfaction scores, and synthesized social data.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005422/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
